Search Within

Population Sciences Research Program

  1. "Larry Norton"
  2. "Mary Ellen Moynahan"
Formats
  1. Journal Article (13)
  2. Meeting Abstract (8)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (21)
  2. Breast Medicine Service (21)
  3. Department of Medicine (21)
  4. Solid Tumor Oncology Division (21)
  5. Biostatistics Service (19)
  6. Epidemiology and Biostatistics (19)

More Groups

People
  1. Larry Norton (21)
  2. Mary Ellen Moynahan (21)
  3. Clifford Hudis (19)
  4. Gabriella D'Andrea-Carlino (17)
  5. Monica Fornier (14)
  6. Diana Lake (13)

More People

Years
  1. 2020 (1)
  2. 2015 (3)
  3. 2013 (1)
  4. 2011 (2)
  5. 2009 (1)
  6. 2008 (2)

More Years

Publications
  1. Breast Cancer Research and Treatment (6)
  2. Journal of Clinical Oncology (5)
  3. Clinical Cancer Research (4)
  4. Cancer Research (3)
  5. Clinical Breast Cancer (1)
  6. Nature Cancer (1)

More Publications

Publishers
  1. American Association for Cancer Research (7)
  2. Springer (6)
  3. American Society of Clinical Oncology (5)
  4. American Association for the Advancement of Science (1)
  5. Elsevier Inc. (1)
  6. Nature Research (1)

Results (21)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
    Journal Article

    Razavi, P.; Dickler, M. N.; Shah, P. D.; Toy, W.; Brown, D. N.; Won, H. H.; Li, B. T.; Shen, R.; Vasan, N.; Modi, S.; more...
    Nature Cancer (2020)

    Fulltext@MSK | Save
  • Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Hamilton, N.; Caravella, B. A.; Zamora, S.; Dang, C.; Gilewski, T.; Traina, T.; Comen, E.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    Journal Article

    Dang, C.; Iyengar, N.; Datko, F.; D'Andrea, G.; Theodoulou, M.; Dickler, M.; Goldfarb, S.; Lake, D.; Fasano, J.; Fornier, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer with cardiac biomarker data
    Meeting Abstract

    Iyengar, N. M.; Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Goldfarb, S.; Theodoulou, M.; Lake, D.; Fornier, M. N.; Modi, S.; Fasano, J.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • A feasibility study of bevacizumab plus dose-dense doxorubicin- cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer
    Journal Article

    Mcarthur, H. L.; Rugo, H.; Nulsen, B.; Hawks, L.; Grothusen, J.; Melisko, M.; Moasser, M.; Paulson, M.; Traina, T.; Patil, S.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Breast cancer methylomes establish an epigenomic foundation for metastasis
    Journal Article

    Fang, F.; Turcan, S.; Rimner, A.; Kaufman, A.; Giri, D.; Morris, L. G. T.; Shen, R.; Seshan, V.; Mo, Q.; Heguy, A.; more...
    Science Translational Medicine (2011)

    Fulltext@MSK | Save
  • A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma
    Journal Article

    Sugarman, S.; Wasserheit, C.; Hodgman, E.; Coglianese, M.; D'alessandro, A.; Fornier, M.; Troso-Sandoval, T.; D'Andrea, G.; Drullinsky, P.; Lake, D.; more...
    Breast Cancer Research and Treatment (2009)

    Fulltext@MSK | Save
  • The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer
    Journal Article

    Dang, C.; Fornier, M.; Sugarman, S.; Troso-Sandoval, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Dickler, M.; Currie, V.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible
    Journal Article

    Dang, C.; D'Andrea, G.; Lake, D.; Sugarman, S.; Fornier, M.; Moynahan, M. E.; Gilewski, T.; Hurria, A.; Mills, N.; Troso-Sandoval, T.; more...
    Clinical Breast Cancer (2008)

    Fulltext@MSK | Save